CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.

IF 8.2 1区医学 Q1 HEMATOLOGY

Haematologica Pub Date : 2024-09-01 DOI:10.3324/haematol.2023.284241

Xin Jin, Rui Sun, Zhu Li, Xianwu Wang, Xia Xiong, Wenyi Lu, Hairong Lyu, Xia Xiao, Yunpeng Tian, Hongkai Zhang, Zhihong Fang, Luqiao Wang, Mingfeng Zhao

引用次数: 0

查看原文本刊更多论文

CD22靶向糖工程自然杀伤细胞为B细胞急性淋巴细胞白血病的治疗提供了新的选择。

不详。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Haematologica 医学-血液学

CiteScore

14.10

自引率

2.00%

发文量

349

审稿时长

3-6 weeks

期刊介绍： Haematologica is a journal that publishes articles within the broad field of hematology. It reports on novel findings in basic, clinical, and translational research. Scope: The scope of the journal includes reporting novel research results that: Have a significant impact on understanding normal hematology or the development of hematological diseases. Are likely to bring important changes to the diagnosis or treatment of hematological diseases.

文献相关原料

公司名称	产品信息	采购帮参考价格